{"filings":[{"id":95008,"accession_number":"0001724521-26-000032","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Q1 net loss $128M, cash $876M; discontinues Phase 3 STAR-121 in NSCLC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $128M for Q1 2026 vs $112M Q1 2025; revenue $17M down from $28M.","Cash $876M at Mar 31, 2026, down from $1.0B at Dec 31, 2025; expect ~$600M year-end, runway to H2 2028.","Discontinued Phase 3 STAR-121 (domvanalimab) in NSCLC after futility analysis (OS not improved vs pembrolizumab+chemo).","Pipeline: casdatifan Phase 3 PEAK-1 enrolling; 1L Phase 3 initiation expected year-end; new I&I candidate AB102 entering clinic Q3 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":17000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95007,"accession_number":"0001724521-26-000021","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Arcus discontinues Phase 3 STAR-121 NSCLC trial; Gilead lets option rights lapse","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["STAR-121 evaluating domvanalimab + zimberelimab + chemo vs pembro + chemo in 1L metastatic NSCLC stopped by IDMC for futility.","Zimberelimab + chemo showed comparable overall survival vs pembro + chemo; trial discontinued despite that.","Gilead declines option continuation payment; option period ends July 14, 2026; loses rights to CCR6, CD89, CD40L programs.","Gilead retains time-limited options for AB801 (AXL inhibitor), AB598 (anti-CD39), AB102 (MRGPRX2 antagonist), and TNF small molecule.","Arcus retains full rights to casdatifan program except Taiho territories (Japan and certain Asian countries)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107774,"accession_number":"0001724521-26-000014","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Arcus Biosciences COO Jennifer Jarrett resigns effective March 30, 2026; advisory role through June 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["COO Jennifer Jarrett resigns effective March 30, 2026; departure not due to any disagreement with company.","Separation agreement includes advisory services through June 30, 2026, and extends post-termination option exercise period to 12 months.","Agreement includes a standard release of claims; final separation agreement to be filed with next 10-Q.","No replacement for COO position has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107773,"accession_number":"0001724521-26-000007","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Biosciences reports Q4 net loss $106M; casdatifan shows 45% cORR in late-line kidney cancer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net loss $106M vs $94M YoY; revenue $33M; cash, equivalents & marketable securities $1.0B.","Casdatifan 100mg QD in late-line ccRCC: confirmed ORR 45.2%, median PFS 15.1 months (Jan 30, 2026 cut).","Full-year 2026 GAAP revenue guidance $45-55M; R&D expenses expected to decrease meaningfully.","Phase 3 PEAK-1 (casdatifan + cabozantinib) enrolling globally; 1L Phase 3 planned by end 2026.","First inflammation program (oral MRGPRX2 antagonist) to enter clinic in 2026; oral TNF inhibitor in late 2026/early 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":247000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124158,"accession_number":"0001724521-25-000122","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Arcus Biosciences amends loan agreement to access up to $150M tied to clinical and FDA milestones","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["First Amendment to Loan and Security Agreement with Hercules Capital dated December 18, 2025.","Up to $50M available after announcement of Phase 3 data supporting FDA filing; $50M after FDA approval.","$50M available at company's sole option through March 2026 and September 2026 ($25M each).","Maturity extended to September 1, 2030.","Performance covenants apply if draws exceed $200M: market cap ≥ $1.5B or cash/revenue thresholds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124157,"accession_number":"0001724521-25-000120","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Arcus ends Phase 3 STAR-221 domvanalimab study on futility; no OS benefit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 STAR-221 of domvanalimab + zimberelimab + chemo vs nivolumab + chemo stopped for futility after IDMC review.","Domvanalimab combo did not improve overall survival vs nivolumab + chemo; safety profile similar.","Phase 2 EDGE-Gastric also discontinued; company and Gilead communicating with investigators.","R&D focus shifts to HIF-2a inhibitor casdatifan and small molecule inflammation programs; MRGPRX2 inhibitor clinical entry expected 2026.","Cash runway expected to fund operations until at least second half 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124156,"accession_number":"0001193125-25-262589","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arcus Biosciences closes public offering of 15.76M shares, net proceeds ~$269.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 15,755,000 shares at $18.25 per share including full exercise of underwriters' option.","Net proceeds of approximately $269.7 million after discounts and estimated expenses.","Underwriters led by Leerink Partners LLC and Goldman Sachs & Co. LLC.","Offering closed on November 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124155,"accession_number":"0001724521-25-000114","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Biosciences reports Q3 2025 net loss $135M; casdatifan shows 12.2 mo mPFS in late-line kidney cancer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $135M for Q3 2025 vs $92M in Q3 2024; revenue $26M vs $48M.","Casdatifan pooled analysis (n=121) showed 12.2 months median PFS and 35% ORR at 100mg dose in late-line ccRCC.","Taiho exercised option for casdatifan in Japan/Asia for option payment, milestones, and royalties.","Cash and equivalents $841M; funded through PEAK-1 Phase 3 readout.","Domvanalimab + zimberelimab + chemo showed 26.7 months median OS in EDGE-Gastric study."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":214000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124154,"accession_number":"0001724521-25-000109","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Arcus Bio's EDGE-Gastric Ph2 shows median OS 26.7 months; ORR 59%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median OS 26.7 months (90% CI: 18.4, NE) for all patients (n=41); PD-L1 high subgroup NE.","Confirmed ORR 59% (24/41) per RECIST v1.1; 62% in PD-L1 positive and 69% in PD-L1 high subgroups.","Median PFS 12.9 months overall; 24-month OS rate 50.2% and PFS rate 25.9%.","Median follow-up 26.4 months; median time on domvanalimab+zimberelimab+chemo was 49 weeks.","No unexpected safety signals; immune-mediated TEAEs in 22% of patients, infusions reactions in 7%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124153,"accession_number":"0001724521-25-000107","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Arcus reports ARC-20 Phase 1/1b data: pooled ORR 31%, median PFS 12.2 mo; unveils 5 I&I preclinical programs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ARC-20 pooled analysis (n=121) in ccRCC: 31% confirmed ORR [95% CI 23-40], median PFS 12.2 mo (9.4-20.6).","50 mg QD cohort showed 36% ORR (incl. pending) and median PFS 19.2 mo; 100 mg QD showed 42% ORR (incl. pending).","Safety: Grade≥3 anemia 41%, hypoxia 11%; discontinuation rate 3%; no unexpected signals as of Aug 15, 2025 DCO.","Five new preclinical programs disclosed: MRGPRX2, TNFR1, CCR6, CD89, CD40L; first clinical study targeted in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140827,"accession_number":"0001724521-25-000099","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Biosciences Q2 2025 rev $160M (incl $143M one-time), net income breakeven; casdatifan Phase 3 trials initiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents & marketable securities: $927M at June 30, 2025 (Dec 31, 2024: $992M).","Q2 2025 revenue $160M vs $39M YoY, driven by $143M cumulative catch-up from etrumadenant program pause.","R&D expenses $139M (vs $115M Q2 2024); CMC costs expected elevated through Q3, then decline from Q4.","PEAK-1 (Phase 3 casdatifan + cabozantinib) and eVOLVE-RCC02 (Phase 1b/3 with AstraZeneca) initiated in ccRCC.","Quemliclustat granted FDA Orphan Drug Designation for pancreatic cancer; PRISM-1 enrollment completion expected Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":188000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158569,"accession_number":"0001724521-25-000078","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Arcus annual meeting elects directors, ratifies E&Y, approves say-on-pay; board revises director comp","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four Class I director nominees elected with >86M votes each (broker non-votes ~8.6M).","Ernst & Young ratified as auditor for FY2025 with 96.8M votes for (96.3% of votes cast).","Advisory 'say-on-pay' approved with 84.8M for (93.9% of votes cast excluding abstentions).","Board revised Non-Employee Director Compensation Program: $50k cash retainer, $750k initial equity, $400k annual equity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158568,"accession_number":"0001724521-25-000066","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"Arcus reports 46% confirmed ORR for casdatifan + cabozantinib in ccRCC post-immunotherapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1/1b ARC-20 interim analysis shows 46% cORR (11/24) per RECIST v1.1; median follow-up 5.3 months.","Response includes 1 complete response (4%) and 10 partial responses (42%); 50% had stable disease.","Safety evaluable population (n=42) showed acceptable safety profile with no new unexpected risks or overlapping toxicity.","Study evaluates casdatifan 100mg QD plus cabozantinib 60mg QD in patients with ccRCC who progressed on prior immunotherapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158567,"accession_number":"0001724521-25-000061","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Q1 net loss widens to $112M; cash $1.0B; casdatifan Phase 3 to start Q2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue fell to $28M from $145M YoY; full-year 2025 revenue guidance $75M-$90M.","Net loss of $112M vs $4M in Q1 2024; R&D expenses rose to $122M from $109M.","Cash, equivalents, marketable securities $1.0B; sufficient to fund through initial pivotal readouts.","Phase 3 PEAK-1 trial of casdatifan + cabozantinib in ccRCC expected to initiate Q2 2025.","FDA feedback on etrumadenant supports registrational path but Arcus not pursuing Phase 3 now."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":28000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176965,"accession_number":"0001724521-25-000039","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Q4 2024 net loss $94M; casdatifan shows best-in-class potential in ccRCC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Revenue $36M for Q4 2024 ($31M Q4 2023); net loss widened to $94M from $81M.","Cash & marketable securities $992M as of Dec 31, 2024, up from $866M year-end 2023.","Casdatifan monotherapy in IO/VEGFR-TKI experienced ccRCC achieved 30%+ ORR, 9.7-month median PFS (50mg BID).","Phase 3 PEAK-1 (casdatifan + cabozantinib vs cabo in post-IO ccRCC) expected to initiate Q2 2025.","Domvanalimab/zimberelimab Phase 3 STAR-221 top-line data for 1L upper GI cancers expected 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176964,"accession_number":"0001193125-25-029591","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arcus Biosciences raises ~$141.6M in public offering of 13.6M shares at $11.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 13,636,364 shares at $11.00/share, yielding ~$141.6M net proceeds after expenses.","Proceeds to fund R&D activities, including clinical development of casdatifan, manufacturing, and general corporate purposes.","Offering closed on Feb 19, 2025; underwritten by Goldman Sachs and Leerink Partners.","Shares sold under existing shelf registration statement (Form S-3) filed with the SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176963,"accession_number":"0001193125-25-028110","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Arcus reports $992M cash; Gilead opts out of casdatifan; ARC-20 data shows ORR 25-33%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents and marketable securities of $992M as of Dec 31, 2024.","Gilead's exclusive option for casdatifan expired without exercise; Arcus retains full global rights.","ARC-20 in ccRCC: 50mg BID median PFS 9.7 months, ORR 25%; 100mg QD ORR 33%.","Disease control rate 81-87% across cohorts; median DoR not reached; safety acceptable.","All but two of 26 responders remained on treatment; one discontinuation due to anemia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176962,"accession_number":"0001724521-25-000024","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Arcus Biosciences appoints Dietmar Berger to board replacing Merdad Parsey","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Merdad Parsey resigned from Arcus board effective upon Gilead's new director designee; he left Gilead.","Dietmar Berger, Gilead's CMO since Jan 2025, appointed as Class II director to fill vacancy.","Dr. Berger will not receive compensation for board service; Arcus will enter standard indemnification agreement.","Changes made pursuant to Amended and Restated Investor Rights Agreement between Arcus and Gilead."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176961,"accession_number":"0001724521-25-000005","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Arcus appoints Richard Markus as CMO; Dimitry Nuyten departs Jan 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Markus, M.D., Ph.D., named Chief Medical Officer, effective January 31, 2025.","Dimitry Nuyten, M.D., Ph.D., will depart from Arcus on the same date.","Dr. Nuyten eligible for lump-sum severance of 12 months base salary, 12 months COBRA, and 2024 bonus.","Separation agreement details described; final agreement to be filed after execution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193756,"accession_number":"0001724521-24-000159","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Q3 net loss $92M; casdatifan shows 34% ORR, domvanalimab 36% risk reduction","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $92M vs $71M YoY; revenue $48M (up from $32M) on $41M license and development services.","Cash, equivalents and securities $1.1B, providing runway into mid-2027; year-end expected $950M-$985M.","Casdatifan 100mg cohort: 34% ORR (25% confirmed), 19% primary progression, median PFS not reached.","Domvanalimab+zimberelimab reduced risk of death by 36% (HR=0.64) vs zim in 1L NSCLC; median OS not reached.","Clinical collaboration with AstraZeneca to test casdatifan + volrustomig in IO-naive ccRCC."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":232000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193755,"accession_number":"0001724521-24-000153","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"Arcus reports casdatifan interim data: 34% ORR in heavily pre-treated ccRCC patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORR 34% (11/32) in efficacy-evaluable patients at 100 mg dose; confirmed ORR 25% (8/32).","Disease control rate 81%; median progression-free survival not reached (data cutoff Aug 30, 2024).","Patient population heavily pre-treated: 52% had ≥3 prior lines; 61% intermediate IMDC risk.","Grade 3 TEAEs related to casdatifan were 42% (anemia 36%, hypoxia 9%); no deaths or life-threatening events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210074,"accession_number":"0001724521-24-000144","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2024-08-27T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Arcus Biosciences secures up to $250M term loan facility from Hercules Capital; initial $50M funded","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $50M funded; additional $50M available at company's option through Jun 2025 and another $50M through Mar 2026; final $100M at lenders' option.","Interest rate = greater of Prime Rate + 1.95% or 10.45% p.a.; interest-only payments until Sep 2028, extendable 12 months if FDA approves BLA/NDA.","Loans mature Sep 2029, extendable 12 months upon two of three milestones: phase 3 starts for casdatifan, quemliclustat, or etrumadenant.","Covenant: if mkt cap ≤ $1.2B, maintain Qualified Cash ≥ 50% of outstanding principal; threshold reduces to 40% or 35% upon milestones.","Prepayment premium 3% (yr1), 2% (yr2), 1% (thereafter); end-of-term charge 7.75%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210073,"accession_number":"0001724521-24-000136","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus reports Q2 2024 net loss $93M, cash $1.0B; casdatifan data due Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $39M (up from $29M in Q2 2023); net loss $93M vs $75M year-over-year.","Cash, cash equivalents and marketable securities $1.0B, sufficient into 2027; expects $885-925M by year-end 2024.","Casdatifan 100mg ccRCC expansion ORR data expected Q4 2024; PEAK-1 Phase 3 study start H1 2025.","STAR-221 (domvanalimab+chemo) completed enrollment; STAR-121 (NSCLC) expected to complete enrollment in 2024.","Taiho exercised option for quemliclustat in Japan/Asia; Phase 3 PRISM-1 pancreatic cancer to start early 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":184000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228301,"accession_number":"0001724521-24-000101","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Arcus Biosciences adopts amended director compensation; annual meeting passes all proposals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New non-employee director compensation: $45,000 annual cash retainer; $25,000 extra for Lead Independent Director.","Initial equity award: ~$750,000 grant-date value, 2/3 stock options and 1/3 RSUs, vesting over 3 years.","Annual equity award: ~$400,000 grant-date value, vests fully in 12 months or until next annual meeting.","Annual meeting results: all three Class III directors elected; Ernst & Young ratified; say-on-pay approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228300,"accession_number":"0001724521-24-000099","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"Arcus reports Phase 2 EDGE-Gastric interim data: median PFS 12.9 months, ORR 58.5% in upper GI cancers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median PFS of 12.9 months (95% CI 9.8–13.8) across 41 patients in the domvanalimab+zimberelimab+chemo arm.","Confirmed ORR 58.5%, with 3 complete responses and median DOR of 12.4 months (95% CI 9.9–NE).","PD-L1-high subgroup (TAP ≥5%) showed median PFS 13.8 months and ORR 68.8% (n=16).","No unexpected safety signals; infusion-related reactions in 19.5% of subjects, mostly chemotherapy-related.","Data cutoff March 12, 2024; results posted to company website on June 2, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228299,"accession_number":"0001724521-24-000096","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ARC-9 interim analysis: EZFB combo improves PFS (HR 0.27) and OS (HR 0.37) vs regorafenib in 3L mCRC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cohort B (n=112) met primary endpoint: PFS HR 0.27 (p<0.0001), median 6.2 vs 2.1 months.","OS key secondary: HR 0.37 (p=0.0003), median OS 19.7 vs 9.5 months favoring EZFB.","ORR 17.3% for EZFB vs 2.7% for regorafenib; safety profile consistent with FOLFOX/bev.","Data selected for oral presentation at 2024 ASCO Annual Meeting on June 2, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228298,"accession_number":"0001724521-24-000090","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Q1 revenue jumps to $145M, net loss $4M; pipeline advances with ASCO presentations and Phase 3 enrollments","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $145M vs $25M YoY, including $135M license revenue from Gilead collaboration amendments.","Net loss $4M vs $80M YoY; cash $1.1B at quarter end; year-end 2024 cash expected $870-920M.","R&D expenses $109M (up from $81M); $20M impairment charge for facility sublease.","Two oral presentations at ASCO 2024: EDGE-Gastric (domvanalimab) and ARC-9 (etrumadenant) in GI cancers.","Phase 3 STAR-221 enrollment expected mid-2024; STAR-121 H2 2024; first Phase 3 for casdatifan in ccRCC planned H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":145000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}